Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 6/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337212 | 1.00 | DYRK1A (0.45) | DYRK1ADYRK1BMKNK1MKNK2EGFR | |
| SCHEMBL28987589 | 0.89 | DYRK1A (0.42) | DYRK1ADYRK1BMKNK1MKNK2EGFR | |
| SCHEMBL30337352 | 0.89 | DYRK1A (0.42) | DYRK1ADYRK1BMKNK1MKNK2EGFR | |
| SCHEMBL30337162 | 0.88 | DYRK1A (0.46) | DYRK1ADYRK1BMKNK1MKNK2EGFR | |
| SCHEMBL28384419 | 0.88 | DYRK1A (0.46) | DYRK1ADYRK1BMKNK1MKNK2EGFR | |
| SCHEMBL17490471 | 0.86 | DYRK1A (0.45) | DYRK1ADYRK1BMKNK1MKNK2EGFR | |
| SCHEMBL30459718 | 0.85 | DYRK1A (0.44) | DYRK1ADYRK1BMKNK1MKNK2EGFR | |
| SCHEMBL17683321 | 0.85 | DYRK1A (0.44) | DYRK1ADYRK1BMKNK1MKNK2EGFR | |
| SCHEMBL30337177 | 0.83 | DYRK1A (0.44) | DYRK1ADYRK1BMKNK1MKNK2EGFR | |
| SCHEMBL28987593 | 0.83 | DYRK1A (0.44) | DYRK1ADYRK1BMKNK1MKNK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974845-A | Preparation method of oxitinib intermediate | 奥锐特药业股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-3205650-B1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10428081-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-10-01 | — | — | US | disclosed |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-16 | — | — | US | disclosed |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-04 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | DYRK1A 1620/4885DYRK1B 1543/4885MKNK1 2279/4885 |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | DYRK1A 472/4885DYRK1B 425/4885MKNK1 2644/4885 |
| US-10428081-B2 | EGFR inhibitor, preparation method and use thereof | EGFR, ERBB2, ERBB4 | DYRK1A 472/4885DYRK1B 425/4885MKNK1 2644/4885 |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | EGFR, ERBB2, ERBB4 | DYRK1A 1620/4885DYRK1B 1543/4885MKNK1 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.